Progress of targeted therapy for multiple myeloma / 白血病·淋巴瘤

ABSTRACT

With the wide clinical application of proteasome inhibitors (PI), immunomodulary drugs (IMiD) and autologous stem cell transplantation (ASCT), the prognosis of multiple myeloma (MM) patients has been dramatically improved. However, MM is still an incurable disease, becoming relapse or disease progression finally. Therefore, the development of new drugs with varying mechanisms and the improvement of treatment regimens can help to eradicate the tumor clone and deepen the degree of disease remission. Although most new agents are in different stages of clinical trials, the emerging development of novel agents abroad currently has made MM patients obtain deeper and more enduring remission according to the early experimental data, adding the good safety and efficacy of the new drugs, which could bring the promising clinical application. Varieties of novel drugs combined with PI or IMiD could provide new treatment regimens for MM. This paper reviews the recent progress of the targeted novel drugs of MM.